Boehringer Ingelheim launches Pradaxa in UK
16 August 2011 00:00 in Pharmaceutical Company Product News
Boehringer Ingelheim is launching Pradaxa, its innovative treatment for stroke prevention among atrial fibrillation patients, in the UK this week.
The oral anticoagulant has been licensed for sale in Britain and becomes the first new therapy of its kind to be introduced in more than 50 years when it becomes available on August 18th 2011.
Earlier this month, it was announced that the European Commission has approved a label extension for the drug in this specification, following similar positive decisions in the US, Japan, Australia and other territories.
Regulatory backing was based on positive data from the RE-LY phase III study, which showed the safety and efficacy of the drug compared to warfarin.
The launch will help to assist those suffering from atrial fibrillation, the UK's most common heart rhythm condition and a leading cause of stroke.
Professor John Camm, head of the department of cardiac and vascular sciences at St Georges Hospital in London, said: "A new anticoagulant, like Pradaxa, is going to be very important for eligible atrial fibrillation patients."
Other news stories from 16/08/2011
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency